Treatment Windows and Clinical Outcomes in Late-Presenting Patients with ST-Segment Elevation Myocardial Infarction

被引:2
|
作者
Gao, Ming [1 ]
Qin, Ling [1 ]
Zhang, Zhiguo [1 ]
Chen, Liping [2 ]
Zheng, Yang [1 ]
Tong, Qian [1 ]
Liu, Quan [1 ]
机构
[1] Jilin Univ, Hosp 1, Dept Cardiol, Changchun, Jilin, Peoples R China
[2] Jilin Univ, Hosp 1, Dept Echocardiog, Changchun, Jilin, Peoples R China
来源
关键词
Time window; Recurrent myocardial infarction; ST-segment elevation myocardial infarction; Primary percutaneous coronary intervention; PERCUTANEOUS CORONARY INTERVENTION; NO-REFLOW PHENOMENON; VENTRICULAR DYSFUNCTION; PRIMARY ANGIOPLASTY; SYMPTOM ONSET; REPERFUSION; TIME; ARTERY; OCCLUSION; THERAPY;
D O I
10.1016/j.amjms.2019.04.026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Percutaneous coronary intervention (PCI) is the reperfusion strategy typically used in patients with ST-segment elevation myocardial infarction (STEMI) who present with prolonged ischemic symptoms (>12 hours after onset). However, there is no consensus on an optimal time window for PCI. We examined a real-world cohort, assessing time from symptom onset to balloon inflation in relation to long-term nonfatal recurrent myocardial infarction (MI) or all-cause mortality. Materials and Methods: A total of 825 consecutive patients presenting with ischemic symptoms of STEMI >12 hours after symptom onset and undergoing subsequent primary PCI were grouped by time-to-treatment status (<= 7 days or >7 days post-MI). Primary endpoints were nonfatal recurrent MI and all-cause mortality. Results: Cumulative rates of recurrent nonfatal MI at 2 years were 4.1% and 3.3% in patients with symptom-onset-to-balloon inflation times of <= 7 days and >7 days, respectively (P = 0.049); and corresponding mortality rates were 3.4% and 4.7% (P = 0.238). In Cox multivariate analyses, syndrome-onset-to-balloon-inflation time was not independently predictive of recurrent MI (P = 0.052) or mortality (P = 0.651) at 2 years, once adjusted for certain clinical and angiographic variables known to influence patient outcomes. The 2-year rate of recurrent MI was highest in patients with multivessel coronary artery diseases undergoing primary PCI <= 7 days after symptom onset to balloon inflation (P = 0.005). Conclusions: In patients presenting with ischemic signs or symptoms of STEMI >12 hours after initial symptom onset and treated by PCI, symptom-onset-to-balloon-inflation times <= 7 days showed no relation to nonfatal recurrent MI, unless in the presence of multivessel coronary artery diseases.
引用
收藏
页码:248 / 255
页数:8
相关论文
共 50 条
  • [41] ST-Segment Elevation Myocardial Infarction
    Younis, George A.
    TEXAS HEART INSTITUTE JOURNAL, 2022, 49 (05) : 111 - 111
  • [42] ST-segment elevation myocardial infarction
    Vogel, Birgit
    Claessen, Bimmer E.
    Arnold, Suzanne, V
    Chan, Danny
    Cohen, David J.
    Giannitsis, Evangelos
    Gibson, C. Michael
    Coto, Shinya
    Katus, Hugo A.
    Kerneis, Mathieu
    Kimura, Takeshi
    Kunadian, Vijay
    Pinto, Duane S.
    Shiomi, Hiroki
    Spertus, John A.
    Steg, P. Gabriel
    Mehran, Roxana
    NATURE REVIEWS DISEASE PRIMERS, 2019, 5 (1)
  • [44] Bivalirudin in patients with ST-segment elevation myocardial infarction
    Coughlan, J. J.
    Kastrati, Adnan
    LANCET, 2022, 400 (10366): : 1822 - 1823
  • [45] Primary Percutaneous Coronary Intervention for Patients Presenting With ST-Segment Elevation Myocardial Infarction: Process Improvement in a Rural ST-Segment Elevation Myocardial Infarction Receiving Center
    Niles, Nathaniel W.
    Conley, Sheila M.
    Yang, Rayson C.
    Vanichakarn, Pantila
    Anderson, Tamara A.
    Butterly, John R.
    Robb, John F.
    Jayne, John E.
    Yanofsky, Norman N.
    Proehl, Jean A.
    Guadagni, Donald F.
    Brown, Jeremiah R.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2010, 53 (03) : 202 - 209
  • [46] BivalirudinIn Patients with ST-Segment Elevation Myocardial Infarction
    Monique P. Curran
    Drugs, 2010, 70 : 909 - 918
  • [47] Bivalirudin In Patients with ST-Segment Elevation Myocardial Infarction
    Curran, Monique P.
    DRUGS, 2010, 70 (07) : 909 - 918
  • [48] Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction
    Chen, Yucheng
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (07): : 705 - 706
  • [49] The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction
    Kessler, Daniel P.
    Kroch, Eugene
    Hlatky, Mark A.
    AMERICAN HEART JOURNAL, 2011, 162 (03) : 494 - U111
  • [50] Very Long-Term Clinical Outcomes After Direct Stenting in Patients Presenting With ST-Segment Elevation Myocardial Infarction
    Scarparo, Paola
    Improta, Riccardo
    Wilschut, Jeroen
    Kardys, Isabella
    Den Dekker, Wijnand K.
    Daemen, Joost
    Zijlstra, Felix
    Van Mieghem, Nicolas M.
    Diletti, Roberto
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2022, 41 : 144 - 150